🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07051694
Recruiting Not applicable

Transcutaneous Auricular Vagus Nerve Stimulation as Adjuvant Treatment for Sepsis Patients

NCT07051694 · tracked via the Priya Life Science China tracker
Sponsor
Third Military Medical University
Phase
Not applicable
Started
2025-02-27
Last updated
2025-07-04

Condition(s) studied

Sepsis

Investigational drug(s) / intervention(s)

taVNSsham-taVNS

taVNS: Transcutaneous Auricular Vagus Nerve Stimulation

sham-taVNS: sham transcutaneous auricular vagus nerve stimulation

Study summary

The goals of this randomized clinical trial are to investigate the effects of transcutaneous auricular vagus nerve stimulation (taVNS) combined with standard intensive care on systemic organ function in septic patients, and exploring its potential mechanisms for improving overall outcomes in sepsis.The main question it aims to answer is whether taVNS can reduce the severity of sepsis patients by ameliorating systemic inflammation.Participants will receive standard intensive care treatment and be randomized to receive the taVNS or sham taVNS as adjuvant treatment twice a day for 7 consecutive days. Several evaluations will be done before and after the intervention.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18-80 * Sepsis was diagnosed per the Sepsis-3 criteria (SCCM/ESICM 2016) as infection with SOFA score ≥ 2 * ICU admission within 7 days after sepsis onset * Informed consent was obtained from patients/guardians Exclusion Criteria: * severe ARDS defined by PaO₂/FiO₂ ≤100 mmHg with PEEP ≥5 cm H₂O * HR\>120 per minute * epinephrine or norepinephrine \>1ug/kg/min * severe underlying pulmonary diseases including interstitial lung disease, - * diffuse alveolar hemorrhage, severe asthma, or lung cancer * taVNS contraindications: existing pacemakers, cochlear implants, or other active implantable electronic medical devices * dermatologic or infectious disorders affecting the auricular region * pregnancy or lactation * participation in other clinical trials * inability to remain motionless during treatment (e.g., due to epilepsy or Parkinson's disease)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Army Medical University Chongqing China Recruiting

More Third Military Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07051694 on ClinicalTrials.gov ↗ ← All trials in China